MedTrace Logo

Alternate Dosing Regimens of BG00012 in Healthy Volunteers

NCT01281111 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 56

Last updated 2023-08-23

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety, tolerability, and PK of different doses and dosing regimens of BG00012 administered with and without ASA compared to placebo

Conditions

  • Healthy

Interventions

DRUG

Dimethyl Fumarate (BG00012)

DRUG

Aspirin

DRUG

BG00012 matching placebo

DRUG

ASA matching placebo

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
FACTORIAL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-02-01
Primary Completion
2011-03-18
Completion
2011-03-18

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01281111 on ClinicalTrials.gov